Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

1.050 -0.050 (-4.55%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	182,258
Open	1.100
Bid (Size)	1.050 (8,600)
Ask (Size)	1.140 (200)
Prev. Close	1.100
Today's Range	1.040 - 1.100
52wk Range	0.8401 - 12.23
Shares Outstanding	11,586,406
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026

From Tempest Therapeutics

Via GlobeNewswire

Performance

YTD	-64.4%	-64.4%
1 Month	+18.3%	+18.3%
3 Month	-19.2%	-19.2%
6 Month	-54.5%	-54.5%
1 Year	-90.0%	-90.0%

More News

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

July 15, 2026

From Tempest Therapeutics

Via GlobeNewswire

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

July 07, 2026

Via Chartmill

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

June 04, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

May 29, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 06, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

April 29, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

April 22, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

April 14, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Reports Year End 2025 Financial Results and Provides Business Update

March 30, 2026

From Tempest Therapeutics

Via GlobeNewswire

These stocks are moving in today's session ↗

March 23, 2026

Via Chartmill

Tempest Therapeutics Announces Up To $6 Million Private Placement

March 23, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

March 11, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

February 25, 2026

From Tempest Therapeutics

Via GlobeNewswire

Wednesday's pre-market session: top gainers and losers ↗

February 18, 2026

Via Chartmill

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

February 11, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

February 04, 2026

From Tempest Therapeutics

Via GlobeNewswire

The market is filled with gapping stocks in Thursday's session. ↗

January 22, 2026

Via Chartmill

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

January 20, 2026

From Tempest Therapeutics

Via GlobeNewswire

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

November 26, 2025

From Tempest Therapeutics

Via GlobeNewswire

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

November 25, 2025

From Tempest Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 20, 2025

Via Benzinga

Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition

November 19, 2025

Via MarketMinute

Frequently Asked Questions

Is Tempest Therapeutics, Inc. - Common Stock publicly traded?

Yes, Tempest Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Tempest Therapeutics, Inc. - Common Stock trade on?

Tempest Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Tempest Therapeutics, Inc. - Common Stock?

The ticker symbol for Tempest Therapeutics, Inc. - Common Stock is TPST on the Nasdaq Stock Market

What is the current price of Tempest Therapeutics, Inc. - Common Stock?

The current price of Tempest Therapeutics, Inc. - Common Stock is 1.050

When was Tempest Therapeutics, Inc. - Common Stock last traded?

The last trade of Tempest Therapeutics, Inc. - Common Stock was at 09/03/26 04:00 PM ET

What is the market capitalization of Tempest Therapeutics, Inc. - Common Stock?

The market capitalization of Tempest Therapeutics, Inc. - Common Stock is 12.17M

How many shares of Tempest Therapeutics, Inc. - Common Stock are outstanding?

Tempest Therapeutics, Inc. - Common Stock has 12M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.